Protara Therapeutics to Participate in Upcoming Investor Conferences
March 01, 2023 08:00 ET
|
Protara Therapeutics
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
February 02, 2023 08:00 ET
|
Protara Therapeutics
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Appointment of Patrick Fabbio as Chief Financial Officer
January 30, 2023 08:00 ET
|
Protara Therapeutics
NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 23rd Annual Meeting of the Society of Urologic Oncology
December 01, 2022 08:00 ET
|
Protara Therapeutics
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Third Quarter 2022 Financial Results and Business Overview
November 03, 2022 08:00 ET
|
Protara Therapeutics
- Dose Escalation Ongoing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Following Recent Feedback from the U.S. Food and Drug Administration,...
Protara Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 08:00 ET
|
Protara Therapeutics
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Second Quarter 2022 Financial Results and Business Overview
August 09, 2022 08:00 ET
|
Protara Therapeutics
- Enrollment Progressing in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer - - Strong Cash, Cash Equivalents and Investments Position of $112.8M as of...
Protara Therapeutics Announces Departure of Chief Financial Officer
June 21, 2022 08:00 ET
|
Protara Therapeutics
NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting
May 26, 2022 17:11 ET
|
Protara Therapeutics
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 08:00 ET
|
Protara Therapeutics
NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...